French study supports findings that Pfizer-BioNTech doesn’t risk CVD in old
BNT162b2 or Pfizer-BioNTech mRNA COVID-19 vaccine does not increase the short-term risk for serious cardiovascular adverse events in older people.
A French population-based study provides further evidence that no increased risk of myocardial infarction (MI), stroke, or pulmonary embolism (PE) following vaccination exists in adults aged 75 years or older in the 14 days following vaccination.
“These findings regarding the BNT162b2 vaccine’s short-term cardiovascular safety profile in older people are reassuring. They should be taken into account by doctors when considering implementing a third dose of the vaccine in older people,” said Dr Marie Joelle Jabagi, from the French National Agency for Medicines and Health Products Safety.